Loading...
Artiva Biotherapeutics, Inc.
ARTV•NASDAQ
HealthcareBiotechnology
$2.11
$0.15(7.65%)
Artiva Biotherapeutics, Inc. (ARTV) Financial Performance & Statements
Review Artiva Biotherapeutics, Inc.’s income statement, balance sheet, and cash flow reports with annual and quarterly breakdowns to understand its financial health and growth.
Revenue Growth
-99.25%
↓ 99.25%
Operating Income Growth
-119.37%
↓ 119.37%
Net Income Growth
-111.20%
↓ 111.20%
Operating Cash Flow Growth
-16.03%
↓ 16.03%
Operating Margin
-26806.37%
↓ 26806.37%
Gross Margin
100.00%
↑ 100.00%
Net Profit Margin
-21986.85%
↓ 21986.85%
ROE
-1009.50%
↓ 1009.50%
ROIC
-34.10%
↓ 34.10%
Artiva Biotherapeutics, Inc. (ARTV) Financial Statements
Explore quarterly and annual reports including balance sheet, income statement, cash flow for Artiva Biotherapeutics, Inc. stock.
| Metric | Q4 2024 | Q3 2024 | Q2 2024 | Q1 2024 |
|---|---|---|---|---|
| Revenue | $0.00 | $0.00 | $0.00 | $251000.00 |
| Cost of Revenue | $0.00 | $0.00 | $0.00 | $0.00 |
| Gross Profit | $0.00 | $0.00 | $0.00 | $251000.00 |
| Gross Profit Ratio | $0.00 | $0.00 | $0.00 | $1.00 |
| R&D Expenses | $13.32M | $13.52M | $12.33M | $11.16M |
| SG&A Expenses | $4.95M | $4.81M | $3.86M | $3.59M |
| Operating Expenses | $18.27M | $18.34M | $16.19M | $14.74M |
| Total Costs & Expenses | $18.27M | $18.34M | $16.19M | $14.74M |
| Interest Income | $2.18M | $1.85M | $0.00 | $650000.00 |
| Interest Expense | $0.00 | $0.00 | $0.00 | $0.00 |
| Depreciation & Amortization | $614000.00 | $627000.00 | $603000.00 | $587000.00 |
| EBITDA | -$17.65M | -$17.71M | -$15.59M | -$13.90M |
| EBITDA Ratio | -$55.40 | |||
| Operating Income | -$18.27M | -$18.34M | -$16.19M | -$14.49M |
| Operating Income Ratio | -$57.74 | |||
| Other Income/Expenses (Net) | $9.05M | $863000.00 | $1.65M | $529000.00 |
| Income Before Tax | -$9.21M | -$17.47M | -$14.54M | -$13.96M |
| Income Before Tax Ratio | -$55.63 | |||
| Income Tax Expense | $0.00 | $0.00 | $0.00 | -$382000.00 |
| Net Income | -$9.21M | -$17.47M | -$14.54M | -$13.96M |
| Net Income Ratio | -$55.63 | |||
| EPS | -$0.82 | -$0.92 | -$0.62 | -$0.79 |
| Diluted EPS | -$0.82 | -$0.92 | -$0.62 | -$0.79 |
| Weighted Avg Shares Outstanding | $11.26M | $18.90M | $23.28M | $17.58M |
| Weighted Avg Shares Outstanding (Diluted) | $11.26M | $18.90M | $23.28M | $17.58M |
Unlock 25+ Years of Financial Data
Get access to extended historical data, advanced metrics, and more with our premium plan